Rebecca Zwanziger
Nurse Practitioner · Iowa City, IANPI 1609121748
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,935 of the $4,090 with a category attached, or 71.8%. 19 manufacturers reported payments, led by Lundbeck LLC at 45.4% of the total. Reporting peaked in 2024 at $1,374 and has fallen 56.7% since, to $595 in 2025. Among nurse practitioner clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $38.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$2K
- AbbVie$741
- Inspire Medical Systems, Inc.$387
- Biogen$251
- Biohaven Pharmaceutical Holding Company Ltd.$244
- Harmony Biosciences LLC$157
- plus $451 from 13 others
What the payments were for
- Speaking & faculty fees$1,06026%
- Food & beverage$2,93572%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 15 | $1,859 |
| AbbVie | 37 | $741 |
| Inspire Medical Systems, Inc. | 2 | $387 |
| Biogen | 6 | $251 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $244 |
| Harmony Biosciences LLC | 10 | $157 |
| Novartis | 4 | $73 |
| Lilly USA, LLC | 4 | $61 |
| Biohaven Pharmaceuticals, Inc. | 3 | $57 |
| SK Life Science, Inc. | 2 | $41 |
| Amgen | 2 | $39 |
| Amneal Pharmaceuticals LLC | 1 | $30 |
| Eisai Inc. | 1 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Argenx US, Inc. | 1 | $22 |
| Bristol Myers Squibb | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$1,439
- Inspire Upper Airway Stimulation System$387
- QULIPTA$233
- NURTEC ODT$125
- UBRELVY$109
How this compares
$4,090 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 82 | $147,007 |
| UbrelvyUbrogepant | 36 | $50,853 |
| Emgality PenGalcanezumab-Gnlm | 55 | $40,001 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 41 | $36,566 |
| Aimovig AutoinjectorErenumab-Aooe | 28 | $27,596 |
| QuliptaAtogepant | 25 | $25,745 |
| Gabapentin | 75 | $959 |
| RizatriptanRizatriptan Benzoate | 46 | $623 |
| Duloxetine Hcl | 47 | $575 |
| Topiramate | 95 | $515 |
| Amitriptyline Hcl | 61 | $507 |
| Ondansetron OdtOndansetron | 36 | $470 |
| Sumatriptan Succinate | 34 | $279 |
| Pregabalin | 17 | $242 |
| Memantine Hcl | 12 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $741 | $76,59861 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Other nurse practitioner in Iowa City
- Julie CoffeyIowa City$31K
- Delores FittonIowa City$8K
- Jennifer FranzwaIowa City$7K
- Elizabeth HindersIowa City$6K
- Nicole MorganDes Moines$106K
- Mary JohnsonDavenport$30K
- Megan Hart FernandezCedar Rapids$19K
- Carla HuberCedar Rapids$18K
- Beth ChiaWest Des Moines$15K
- Margaret KinneyRed Oak$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.